Table 3 Sensitivity of the Plasmodium falciparum patient isolates to a panel of anti-malarial compounds

2.7 ± 0.4

0.5 ± 0.1

13 ± 2

3.6 ± 0.5

27 ± 4

20 ± 2

119 ± 17

42 ± 10

2.6 ± 0.5

0.7 ± 0.1

>10000

3.6 ± 0.7

0.5 ± 0.1

149 ± 10

5.6 ± 0.5

21 ± 4

17 ± 1

105 ± 20

58 ± 7

3.6 ± 0.9

0.7 ± 0.1

>10000

4.7 ± 0.6

1.5 ± 0.5

12 ± 1

6.7 ± 1.1

26 ± 3

36 ± 6

110 ± 23

60 ± 7

2.2 ± 0.8

0.2 ± 0.03

>10000

1.7 ± 0.3

1.1 ± 0.2

150 ± 7

7.4 ± 0.5

16 ± 2

7.7 ± 0.8

24 ± 6

156 ± 17

1.9 ± 0.5

0.4 ± 0.1

>10000

4.1 ± 0.3

1.1 ± 0.2

12 ± 1

5.8 ± 0.8

31 ± 7

27 ± 3

67 ± 18

50 ± 16

1.7 ± 0.2

0.3 ± 0.04

>10000

3.3 ± 0.8

0.6 ± 0.09

12 ± 3

4.2 ± 1.2

27 ± 4

23 ± 3

91 ± 21

22 ± 4

2.6 ± 0.9

0.8 ± 0.04

>10000

3.3 ± 0.7

0.6 ± 0.07

14 ± 3

4.2 ± 0.3

23 ± 7

23 ± 1

77 ± 28

52 ± 10

1.3 ± 0.6

0.7 ± 0.2

62 ± 25

5.5 ± 1.0

1.1 ± 0.3

15 ± 2

7.6 ± 1.7

14 ± 1

23 ± 3

73 ± 22

53 ± 6

5.0 ± 0.9

0.3 ± 0.2

28 ± 7

5.2 ± 0.9

0.8 ± 0.3

374 ± 55

10 ± 3

37 ± 3

6.8 ± 2.9

32 ± 4

289 ± 40

16 ± 5

4.3 ± 1.0

>10000